Saltar al contenido
Merck

Cyclic AMP and afferent activity govern bidirectional synaptic plasticity in striatopallidal neurons.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2014-05-09)
Shana M Augustin, Jeff A Beeler, Daniel S McGehee, Xiaoxi Zhuang
RESUMEN

Recent experimental evidence suggests that the low dopamine conditions in Parkinson's disease (PD) cause motor impairment through aberrant motor learning. Those data, along with computational models, suggest that this aberrant learning results from maladaptive corticostriatal plasticity and learned motor inhibition. Dopaminergic modulation of both corticostriatal long-term depression (LTD) and long-term potentiation (LTP) is proposed to be critical for these processes; however, the regulatory mechanisms underlying bidirectional corticostriatal plasticity are not fully understood. Previously, we demonstrated a key role for cAMP signaling in corticostriatal LTD. In this study, mouse brain slices were used to perform a parametric experiment that tested the impact of varying both intracellular cAMP levels and the strength of excitatory inputs on corticostriatal plasticity. Using slice electrophysiology in the dorsolateral striatum, we demonstrate that both LTP and LTD can be sequentially induced in the same D2-expressing neuron and that LTP was strongest with high intracellular cAMP and LFS, whereas LTD required low intracellular cAMP and high-frequency stimulation. Our results provide a molecular and cellular basis for regulating bidirectional corticostriatal synaptic plasticity and may help to identify novel therapeutic targets for blocking or reversing the aberrant synaptic plasticity that likely contributes to motor deficits in PD.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Dopamina hydrochloride
Sigma-Aldrich
Adenosine 3′,5′-cyclic monophosphate, ≥98.5% (HPLC), powder
Sigma-Aldrich
Adenosine 3′,5′-cyclic monophosphate sodium salt monohydrate, ≥98.0% (HPLC), powder
Supelco
Dopamina hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Dopamine hydrochloride solution, 1.0 mg/mL in methanol with 5% 1 M HCl (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Dopamina hydrochloride, European Pharmacopoeia (EP) Reference Standard